Leverage Analysis Stories
Will Advent Technologies (USA Stocks:ADN) be in financial trouble before October?
 | over a week ago at Macroaxis By Raphi Shpitalnik |
Investing in Advent Technologies Holdings (NASDAQ: ADN) requires careful consideration of its current financial standing, especially given the reported free cash flow loss of 36.7M and total liabilities of 21.3M. With a potential upside of 13.45, there may be opportunities for recovery, but investors should be cautious about the company's ability to generate positive cash flow moving forward. As the market adjusts, reassessing your position could be crucial to navigating the risks associated with this stock.
Main Ideas
Advent Technologies Holdings carries a debt of $21.29 million and has a debt-to-equity ratio of 0.0, indicating that the company is not leveraging debt to boost profits. Continue Reading...- ADN Advent Technologies Holdings
- Latest Will Advent Technologies be in financial trouble before October
- ADN 1.85 -0.01
- Low 1.75
- High 1.93
- Alpha -0.69
- Beta 1.77
- Return On Equity -1.84
- Return On Asset -0.57
- Operating Margin (14.60) %
- Current Valuation 11.76 M
- Shares Outstanding 2.64 M
- Shares Owned By Insiders 16.64 %
- Shares Owned By Institutions 3.50 %
- Number Of Shares Shorted 27.5 K
- Price To Book 0.36 X
- Price To Sales 1.01 X
- Revenue 4.86 M
- Gross Profit 1.66 M
- EBITDA (53.23 M)
- Net Income (71.4 M)
- Cash And Equivalents 46.54 M
- Cash Per Share 0.90 X
- Total Debt 21.29 M
- Debt To Equity 0 %
- Current Ratio 5.16 X
- Book Value Per Share 5.21 X
- Cash Flow From Operations (32.12 M)
- Short Ratio 1.55 X
- Earnings Per Share (37.24) X
- Target Price 0.45
- Number Of Employees 100
- Beta 0.11
- Market Capitalization 4.9 M
- Total Asset 34.74 M
- Retained Earnings (179.16 M)
- Working Capital (3.08 M)
- Net Asset 34.74 M
- Accumulation Distribution 0.0933
- Daily Balance Of Power (0.06)
- Rate Of Daily Change 0.99
- Day Median Price 1.84
- Day Typical Price 1.84
- Market Facilitation Index 0.18
- Price Action Indicator 0.005
- Period Momentum Indicator (0.01)
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
AAR Corp has recently encountered a notable downturn, raising questions among investors about the potential for a rebound. The company, operating in the Aerospace & Defense sector, reported a loss in its latest fiscal year, which ended in May. With total liabilities reaching $1.6 billion and operating expenses at $280.2 million, the financial landscape appears challenging.
| over a week ago at Macroaxis By Ellen Johnson |  |
In the world of investing, timing can be everything. Wrap Technologies, a player in the electronic equipment and scientific instruments sector, has recently caught the eye of investors as it navigates through challenging financial waters. With a net income loss of 30.2M and total liabilities sitting at 25.3M, the company faces significant hurdles.
| over a week ago at Macroaxis By Aina Ster |  |
IMAC Holdings has $1.9 million in liabilities and a debt-to-equity ratio of 0.35, which is fairly typical for its industry. The company's beta is 0.0771, indicating it experiences minimal fluctuations compared to the overall market. This means that while market returns may rise, IMAC's gains are likely to be smaller.
| over two weeks ago at Macroaxis By Ellen Johnson | |
Asana Inc (NASDAQ: ASAN) presents a mixed picture for investors when it comes to its debt situation. With total liabilities reaching approximately $277.9M in short and long-term debt and $268.4M in non-current liabilities, the company is navigating a challenging financial landscape. Despite generating total revenue of $652.5M, Asana reported a significant loss of 257M from continuing operations, raising concerns about its ability to manage its obligations effectively.
| over a month ago at Macroaxis By Gabriel Shpitalnik |  |
In the world of investing, debt can be a double-edged sword. Cingulate, a player in the biotechnology sector, is currently grappling with significant financial challenges. With a net income loss of 21.2M and free cash flow also in the red at 15.3M, the company’s financial health raises eyebrows.
| over a month ago at Macroaxis By Rifka Kats |  |
In the world of investing, timing can be everything. As September approaches, Okeanis Eco Tankers presents an intriguing opportunity for investors looking to navigate the marine transportation sector. With a market value hovering around $29.62, the company has shown resilience despite reporting a net income from continuing operations of 171.9M.
| over a month ago at Macroaxis By Gabriel Shpitalnik | |
In the world of finance, every cloud has a silver lining, and for Lumen Technologies, the upcoming debt obligations in September present a pivotal moment. With total liabilities soaring to $33.6 billion and a staggering net income loss of 10.3 billion, the company faces significant challenges. However, their operating income stands at a respectable $1.2 billion, hinting at potential resilience.
| over a month ago at Macroaxis By Ellen Johnson | |
Investing in Scorpius Holdings stock may present a high-risk opportunity, especially considering its significant liabilities of 22.7M against total stockholder equity of 31.4M, which could amplify losses for leveraged investors. Additionally, with a Treynor Ratio of -0.46, the stock has underperformed relative to its risk, suggesting that it may not be a smart investment for those seeking stable returns.
Key Takeaways
Scorpius Holdings currently has $14.04 million in liabilities and a beta of 1.48, indicating a significant risk relative to the market. The company is expected to outperform during market upswings but may underperform in negative market conditions.| over a month ago at Macroaxis By Vlad Skutelnik |  |
In the world of investing, opportunity often arises from adversity. Dermata Therapeutics (NASDAQ: DRMA) has recently captured investor attention, soaring over 29% despite prevailing market headwinds. This late-stage medical dermatology company, which focuses on developing treatments for various skin conditions, is currently navigating a challenging financial landscape, with a net income loss of 7.8M and retained earnings reflecting a deficit of 53.4M.
| over two months ago at Macroaxis By Rifka Kats | |